Maha KatabiPartner at Sofinnova Ventures
Maha joined Sofinnova as a Partner in 2019. She focuses on development stage investments in therapeutics. Maha is an experienced investor in biopharma companies, with over 18 years in venture capital investing and public equities portfolio management. Prior to founding Oxalis in 2018, Maha was a Partner at Sectoral Asset Management since 2008, where she formed and led a dedicated investment team and advisory board to drive investments in private companies. Additionally, she was a Portfolio Manager for a family of funds, that invested in publicly listed and private healthcare companies. Prior to Sectoral, Maha was Vice-President at Ventures West Management since 2004, She started her venture capital career in 1999 at T2C2 Capital Bio. Maha received her PhD in Pharmacology and BSc in Biology from McGill University, and is a CFA charterholder. She is currently Chair of the board of Exactis Innovation, and serves on the board of BIOQuébec.